A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 26 Jun 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jun 2019.
- 17 Nov 2018 New trial record